Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Immunome gross margin

Gross margin is gross profit as a percentage of revenue.

Immunome has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMNM.

Operating margin-5947.9% · median -935.6%

Net margin-5593.8% · median -669.6%

Advertisement
300 × 250

See a number that looks wrong?